Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ferric carboxymaltose
Drug ID BADD_D00882
Description Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
Indications and Usage Ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB08917
KEGG ID D08920
MeSH ID C522335
PubChem ID 86278165
TTD Drug ID D02ICI
NDC Product Code 59353-363; 64552-4070; 0517-0620; 42973-330; 14593-923
Synonyms ferric carboxymaltose | iron carboxymaltose | iron dextri-maltose | polynuclear iron (III)-hydroxide 4(R)-(poly-(1->4)-o-alpha-D-glucopyranosyl)-oxy-2(R),3(S),5(R), 6-tetrahydroxy-hexanoate | Ferinject | VIT-45 | VIT 45 | injectafer
Chemical Information
Molecular Formula C24H44FeO25-
CAS Registry Number 9007-72-1
SMILES C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO )O)O)O)O.O.[OH-].[O-2].[Fe+3]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retching07.01.07.002-Not Available
Seizure17.12.03.001--
Serum ferritin increased13.11.01.026-Not Available
Skin discolouration23.03.03.005-Not Available
Sneezing22.02.05.011-
Stress fracture15.08.02.002; 12.04.02.003-Not Available
Swelling08.01.03.015--Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.003-Not Available
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Tachycardia02.03.02.007-Not Available
Throat irritation22.02.05.013; 07.05.03.004-Not Available
Throat tightness22.02.05.015; 19.01.02.005-Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Unresponsive to stimuli17.02.05.031-Not Available
Urticaria23.04.02.001; 10.01.06.001-
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007-
Vomiting07.01.07.003-
Wheezing22.03.01.009-
Peripheral swelling02.05.04.015; 08.01.03.053-Not Available
Emotional distress19.04.02.008-Not Available
Abasia17.02.05.035; 08.01.02.007-Not Available
Blood phosphorus decreased13.11.01.015-Not Available
Muscle tightness15.05.03.007-Not Available
Intervertebral disc protrusion15.10.01.004-Not Available
Hyperphosphaturia14.04.03.006; 20.02.01.025-Not Available
Injection site discolouration12.07.03.038; 08.02.03.038; 23.03.03.046--Not Available
Ear discomfort04.03.01.005-Not Available
Pruritus generalised23.03.12.003-Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages